Navigation Links
FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
Date:2/29/2008

ISTIQ is contraindicated in patients with a known hypersensitivity to

PRISTIQ or venlafaxine.

-- PRISTIQ must not be used concomitantly with an MAOI or within 14 days

of stopping an MAOI. Allow 7 days after stopping PRISTIQ before

starting an MAOI.

Warnings and Precautions

-- All patients treated with antidepressants should be monitored

appropriately and observed closely for clinical worsening, suicidality,

and unusual changes in behavior, especially during the first few months

of treatment and when changing the dose. Consider changing the

therapeutic regimen, including possibly discontinuing the medication,

in patients whose depression is persistently worse or includes symptoms

of anxiety, agitation, panic attacks, insomnia, irritability,

hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or

suicidality that are severe, abrupt in onset, or were not part of the

patient's presenting symptoms. Families and caregivers of patients

being treated with antidepressants should be alerted about the need to

monitor patients.

-- Development of a potentially life-threatening serotonin syndrome may

occur with SNRIs and SSRIs, including PRISTIQ, particularly with

concomitant use of serotonergic drugs, including triptans. If

concomitant use is clinically warranted, careful observation of the

patient is advised, particularly during treatment initiation and dose

increases. Concomitant use of PRISTIQ with serotonin precursors is not

recommended.

-- Patients receiving PRISTIQ should have regular monitoring of blood

pressure since sustained increases in blood pressure were observed in

clinical studies. Pre-existing hypertension should be controlled before

starting PRISTIQ. Caution should be exercised in treating patients with


'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
2. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
3. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
4. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
5. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
6. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
9. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
10. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Die Übersetzungen wurden von PRNewswire und ... englischen Version handelt es sich um die ... einer groß angelegten Asthmaumfrage halten ihren Zustand für gut ... [1] als kontrolliert gelten können Die ... vier Denkweisen zugeordnet werden können, die alle von einem ...
(Date:5/23/2013)... ELMSFORD, N.Y. , May 23, 2013  BioScrip, ... the Company will present at the Jefferies 2013 Global ... the Grand Hyatt New York. ... and Hai Tran , Chief Financial ... 11:30 a.m. Eastern Daylight Time.   About ...
(Date:5/23/2013)... May 23, 2013 Patheon Inc ... services to the global pharmaceutical industry, will host a ... Approaches to Testing” on Tuesday, June 4, 2013 at ... manufacturers are required to comply with regulations for cleaning ... with limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... The maker community is a contemporary ... They focus on learning practical skills while applying them ... bringing their ideas to life via crowdfunding. A subgroup ... making projects using biology. Glowing Plant has worked for ... them glow with bioluminescence genes, and has now pursued ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2
... Pipeline Efforts at 27th Annual J.P. Morgan Healthcare Conference ... (Nasdaq: GHDX ) announced today that it ... 18-gene Oncotype DX(R) colon cancer assay. Utilizing more ... the validation study will use prospectively defined endpoints to ...
... Jan. 12 WaferGen Biosystems,Inc. (OTC Bulletin ... gene,expression, genotyping, cell biology and stem cell ... successfully demonstrated the,performance of the company,s SmartChip(TM) ... the platform,s ongoing alpha testing program. ...
... - Trial conducted by Novartis to evaluate safety and ... with ribavirin in patients with genotypes 2 and 3 ... Sciences, Inc. (Nasdaq: HGSI ) today announced ... trial that will evaluate the safety and efficacy of ...
Cached Biology Technology:Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 2Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 3Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 4Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay 5WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 2WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 4WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 5Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 2Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 4Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 5
(Date:5/24/2013)... and grow by avoiding detection and destruction by the ... to eliminate cancer cells; however, there are many factors ... Regulatory T cells are immune cells that function to ... the Journal of Clinical Investigation , researchers led ... T cells that infiltrate tumors express proteins that can ...
(Date:5/23/2013)... Frontiers in Plant Science , ... gene content and promoter evolution among grasses , ... of stretches of DNA that undergo little change in ... not code for any proteins. Some of these evolutionarily ... to regulate the expression of other genes or the ...
(Date:5/23/2013)... which estrogen suppresses lipid synthesis in the liver, UC ... treating certain liver diseases. , With this finding, ... long-held views in the field. Study results appear in ... Signaling . , "The dogma in the steroid receptor ... located in the nucleus respond to steroid hormones by ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
... WASHINGTON To reduce the risk of another ... oil spill, a new report from the National Academy ... in offshore drilling should take a "system safety" approach ... of operation -- from ensuring the integrity of wells ...
... reporting development of a first-of-its-kind technology that could help ... involving nerve gas and other chemical agents back to ... ingredients for the agent. A report on the technique, ... attacks, appears in ACS, journal Analytical Chemistry . ...
... Athens, Ga. When you cut an apple and ... lemon juice, an antioxidant, and the process slows down. ... the brain as Alzheimer,s disease sets in. The underlying cause ... with the creation of free radicals that cause oxidative stress. ...
Cached Biology News:Industry, regulators should take 'system safety' approach to offshore drilling in aftermath of Deepwater Horizon accident, says new report 2Industry, regulators should take 'system safety' approach to offshore drilling in aftermath of Deepwater Horizon accident, says new report 3Antioxidant has potential in the Alzheimer's fight, UGA researchers find 2
Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 6 mg/dL to 100mg/dL. Procedure: 15 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
Biology Products: